Lv72
3950 积分 2023-09-25 加入
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
12天前
已完结
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
1个月前
已完结
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
1个月前
已完结
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2个月前
已完结
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
3个月前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]
7个月前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]
8个月前
已完结
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
8个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
9个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
9个月前
已完结
皖公网安备34019202002308
